Uveitis

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, VP, Itch, Angioedema, Adult, AHS, Teva, Uveitis, Contraindication, Annual report, Headache (journal), Forward-looking statement, Teva Pharmaceuticals, Migraine, Hypersensitivity, Calcitonin, Travel, Annual general meeting, MMD, Failure, TEVA, Investment, Medication, TASE, Anaphylaxis, 2021 Essex County Council election, Index, Patient, Private Securities Litigation Reform Act, Drug, NYSE, 6.5×68mm, COVID-19, Hives, Lists of diseases, Compliance, Excipient, MD, Obesity, Oslo bid for the 2022 Winter Olympics, Rash, Pharmaceutical industry, Vaccine

The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.

Key Points: 
  • The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society (AHS) Annual Meeting held June 9-12, 2022, in Denver, Colorado.
  • Data presentations at AHS included eight abstracts examining real-world use of AJOVY across different patient populations and clinical circumstances.
  • The real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted.
  • As the migraine treatment landscape continues to advance, these data provide important insights about AJOVY in real-world settings and its use as a migraine preventive treatment across a spectrum of patients.

Global Dry Eye Disease Drug Pipeline Research Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Pharmaceutical, Inflammation, Uveitis, II, Duane syndrome, News, Patient, Plastoquinone, RASP, ROS, Mergers and acquisitions, Reactive oxygen species, Clinical trial, Neurotrophic keratitis, Dry eye syndrome, III, Technology, Apoptosis, NDA, Therapy, Discovery, Mitochondrion, Acquisition, Cornea, Veterinary medicine, Pharmaceutical industry, Poultry

This "Dry Eye Disease- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.

Key Points: 
  • This "Dry Eye Disease- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.
  • A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines.
  • The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D.

OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

Retrieved on: 
Thursday, May 19, 2022
Uveitis, American depositary receipt, Telephone, Form, G protein-coupled receptor, Company, U.S. Securities and Exchange Commission, GPCR, Patient, LSE, Allergic conjunctivitis, SEC filing, DED, ADSS, IND, Industry, Pathology, Sale, Therapy, Regulation, ThinkEquity, Ocular neuropathic pain, State Street, Prospectus, Security (finance), GLOBE, Pharmaceutical industry

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the closing of its underwritten public offering of 625,000 American Depository Shares (the ADSs) at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.

Key Points: 
  • LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the closing of its underwritten public offering of 625,000 American Depository Shares (the ADSs) at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.
  • 333-263326) relating to the shares was filed with the Securities and Exchange Commission (SEC) and became effective on May 16, 2022.This offering is being made only by means of a prospectus.
  • OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a life sciences company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing

Retrieved on: 
Monday, May 16, 2022
Uveitis, Telephone, Form, Company, G protein-coupled receptor, U.S. Securities and Exchange Commission, Exercise, GPCR, Patient, LSE, Allergic conjunctivitis, DED, ADSS, ADS, IND, Industry, Nasdaq, Biotechnology, Pathology, Sale, Therapy, ThinkEquity, Ocular neuropathic pain, State Street, American depositary receipt, Prospectus, GLOBE, Pharmaceutical industry

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of an underwritten public offering of 625,000 American Depositary Shares (the ADSs) at a public offering price of $4.00 per ADS.

Key Points: 
  • LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of an underwritten public offering of 625,000 American Depositary Shares (the ADSs) at a public offering price of $4.00 per ADS.
  • In addition, OKYO Pharma has granted the underwriters a 45-day option to purchase up to an additional 93,750 ADSs to cover over-allotments, if any.
  • The Company has received approval to list its ADSs on the Nasdaq Capital Market under the symbol OKYO, and the ADSs are expected to begin trading on May 17, 2022.
  • OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.

Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases

Retrieved on: 
Monday, May 16, 2022
Uveitis, BTK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Psoriatic arthritis, National Medical Products Administration, U.S. Securities and Exchange Commission, Degenerative disease, Patient, HCM, Pharmacokinetics, COVID-19, FDA, Hope, Center for Drug Evaluation and Research, IND, SAN, CDE, Psoriasis, Affibody molecule, AIM, Center, Forward-looking statement, TEC, III, NMPA, Sustainable Stock Exchanges Initiative, Therapy, Private Securities Litigation Reform Act, Cancer, Ankylosing spondylitis, CEO, Pharmaceutical industry

Inmagene is developing the drug candidate to potentially treat immunological diseases.

Key Points: 
  • Inmagene is developing the drug candidate to potentially treat immunological diseases.
  • "This is the third IND clearance Inmagene has obtained since the beginning of 2022," said Dr. Jonathan Wang, Chairman and CEO of Inmagene.
  • IMG-004's improved activity, selectivity, and pharmacokinetic profile in preclinical studies compared to those of other BTK inhibitors point toward a best-in-class potential.
  • IMG-004 is a non-covalent, reversible small molecule inhibitor targeting Bruton's tyrosine kinase (BTK).

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 11, 2022
Research, U.S. Securities and Exchange Commission, Webcast, Macular edema, Cohort, Conference, CLS, Private Securities Litigation Reform Act, SEC, Annual report, ET, Drug development, Annual general meeting, Toxic leukoencephalopathy, SCS, Axitinib, Clinical trial, Investor, COVID-19, Periodic Report of the United States of America to the United Nations Committee Against Torture, ARVO, GLOBE, Uveitis, Company, Foundation, Pharming, Eye, Association, Conference call, Refractive surgery, Bausch & Lomb, Choroid, Retina, Patient, NASDAQ, Association for Research in Vision and Ophthalmology, Society, AMD, ASCRS, Safety, Sale, Cataract, Microinjection, Pharmaceutical industry, Video game, Risk management, Ophthalmology, Clearside

ALPHARETTA, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Clearsides license and other revenue for the first quarter of 2022 was $347,000, compared to $34,000 for the first quarter of 2021.
  • Research and development expenses for the first quarter of 2022 were $4.5 million, compared to $5.5 million for the first quarter of 2021.
  • Clearsides management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

Retrieved on: 
Saturday, April 30, 2022
HCM, Adult, U.S. Securities and Exchange Commission, CEO, Psoriasis, Patient, AIM, FDA, CDE, IND, OX40, COVID-19, Degenerative disease, Food, Cancer, Partnership, SAN, AD, Forward-looking statement, Ligation, Therapy, Private Securities Litigation Reform Act, Sustainable Stock Exchanges Initiative, Lists of diseases, Uveitis, Ankylosing spondylitis, OX40L, Hope, Atopic dermatitis, Affibody molecule, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Generic drug, Vaccine, Pharmaceutical industry

"Research data has given us the confidence that IMG-007 is one of the strongest OX40 drug candidates worldwide," said Dr. Jonathan Wang, Chairman and CEO of Inmagene.

Key Points: 
  • "Research data has given us the confidence that IMG-007 is one of the strongest OX40 drug candidates worldwide," said Dr. Jonathan Wang, Chairman and CEO of Inmagene.
  • "Inmagene is taking many innovative drug candidates like IMG-007 from discovery or candidate stage to global clinical studies."
  • Preclinical research results show that IMG-007 can bind to human OX40 receptor with high affinity, thereby efficiently blocking the binding of OX40 to OX40L.
  • By selectively shutting down OX40+ T cell function, IMG-007 may potentially provide treatment option for pathological OX40+ T cell-mediated immune diseases, such as atopic dermatitis.

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

Retrieved on: 
Tuesday, April 26, 2022
Massachusetts General Hospital, Association, Stanford University, Research, Organization, Patient, SAVE, Johns Hopkins Hospital, Stanford University School of Medicine, Pediatrics, IDEAL, American Ophthalmological Society, FDA, University, Johns Hopkins University, Eye, Macular edema, Massachusetts Eye and Ear, Drug development, Biochemistry, Society, IND, AMD, National Eye Institute, Ranibizumab, Company, Internal medicine, CEO, Public relations, Molecular biophysics, Coronavirus Scientific Advisory Board (Turkey), Master of Science, Association for Research in Vision and Ophthalmology, Diabetic retinopathy, Therapy, DME, KOSDAQ, Clinical trial, Hospital, Neoplasm, Diabetes, Harvard Medical School, Pharmaceutical industry, Vaccine, Uveitis, Ophthalmology, MD, Yale University

"We are very honored to have Professor Nguyen as a new member to our Scientific Advisory Board," commented Dr.Jin-San Yoo, CEO of PharmAbcine.

Key Points: 
  • "We are very honored to have Professor Nguyen as a new member to our Scientific Advisory Board," commented Dr.Jin-San Yoo, CEO of PharmAbcine.
  • His expertise will provide tremendous insights in developing PMC-403, the Company's novel TIE2-activating antibody, for ophthalmology.
  • We look forward to working together with Professor Nguyen as we move toward an IND submission of PMC-403 in 2022."
  • "It is a great pleasure for me to join the Scientific Advisory Board at PharmAbcine," said Professor Nguyen.

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Retrieved on: 
Tuesday, April 26, 2022
Patent, CEO, European Patent Convention, Biotechnology, Multiple sclerosis, Lymphatic system, Retinopathy, NASDAQ, EPO, Immune tolerance, CFO, Laquinimod, Patient, Corneal neovascularization, ACTI, Multiple myeloma, III, EU, Choroidal neovascularization, Eye, United States patent law, European Patent Office, Partnership, Premature, MS, Uveitis, Therapy, Pharmaceutical industry

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotechs patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization.

Key Points: 
  • Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotechs patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization.
  • The patent will be granted on May 11, 2022, under patent number EP 3886858, and provides protection and market exclusivity of laquinimod in this field of use until 2040.
  • The patent covers the medical use of laquinimod for treatment of sight-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy.
  • The now granted European patent of laquinimod further strengthens the protection of laquinimod in devastating eye disorders with high medical need, said Helen Tuvesson, CEO.

Celltrion Healthcare announces the availability of Yuflyma®, a high-concentration, low-volume, citrate-free, and latex-free Humira® (adalimumab) biosimilar in Canada

Retrieved on: 
Monday, April 11, 2022
CONNECT, CGMP, Crohn's disease, Letter, AbbVie, Uveitis, Patient, Adult, Psoriatic arthritis, Celltrion, Program, Ulcerative colitis, Pan-Canadian Pharmaceutical Alliance, Commercial, Psoriasis, EU, Hidradenitis suppurativa, Rheumatoid arthritis, Gastroenterology, Ankylosing spondylitis, Pharmacy, McMaster University, FDA, Division, Health Canada, Pharmaceutical industry, Medical device, Kerosene, Medicine, Adalimumab

"We received a positive letter of intent from the pan-Canadian Pharmaceutical Alliance, with coverage by provincial formularies soon to come.

Key Points: 
  • "We received a positive letter of intent from the pan-Canadian Pharmaceutical Alliance, with coverage by provincial formularies soon to come.
  • With the launch of Yuflyma, Celltrion Healthcare Canada is also proud to offer CELLTRION CONNECT, a patient-focused support program tailored to support patients and healthcare providers.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • YUFLYMA is a registered trademark of Celltrion Inc.
    REMSIMA SC is a trademark of Celltrion Inc.
    HUMIRA is a registered trademark of AbbVie Inc.